GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today the 510(k) submission to the U.S. Food and Drug Administration for CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clearance, will be demonstrated at the Radiological Society of North America's (RSNA) 2024 Annual Meeting t.

GE HealthCare announces 510(k) submission for CleaRecon DL technology designed to improve image quality in the interventional suite with AI-based reconstruction

GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.

GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare to acquire remaining 50% stake in Nihon Medi-Physics (NMP), a leading radiopharmaceutical company in Japan, from Sumitomo Chemical.

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially launched in 2023 for Cardiac MRI, Sonic DL provides up to 12 times scan acceleration while maintaining dia.

GE HealthCare Unveils Sonic DL for 3D, Expanding Deep Learning Innovations in MRI

CHICAGO--(BUSINESS WIRE)--At the Radiological Society of North America's (RSNA) 2024 Annual Meeting taking place from Dec. 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) will exhibit more than 40 innovations, including several key artificial intelligence (AI)-enabled technologies to optimize patient care and increase operational efficiencies. GE HealthCare products are designed to increase efficiency and help seamlessly integrate data to support precision care across multiple care pathways. These.

GE HealthCare Highlights New Solutions Including AI-enabled Innovations to Drive Precision Care at RSNA 2024

The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.

GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care

GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.

GEHC Stock May Gain Following the Launch of Pristina Via System

CHICAGO--(BUSINESS WIRE)--Today GE HealthCare announced the new Pristina Via™* mammography system designed to enhance the screening experience for both technologists and patients. Debuting at the Radiological Society of North America's 2024 Annual Meeting, this innovation provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care. Recent data from the American Soc.

GE HealthCare unveils Pristina Via to streamline technologist workflow and improve patient-centered breast care

GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.

GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Nasdaq Investor Conference in London, England - December 10, 2024 at 11:00 am GMT / 5:00 am CT / 6:00 am ET 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA - January 14, 2025 at 4:15 pm CT / 5:15 pm ET Webcasts of these events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-ev.

GE HealthCare management to present at upcoming investor conferences

CHICAGO--(BUSINESS WIRE)--GE HealthCare announces additional clinical applications now available as part of the OEC 3D mobile CBCT C-arm portfolio.

GE HealthCare Announces Advanced Imaging Innovations for OEC 3D C-arm to Help Improve Precision Care in Practice of Interventional Pulmonology

GE HealthCare hosted an analyst event on Thursday. Solid guidance fell on deaf ears.

GE HealthCare Guidance Was Good. The Stock Dropped Anyway.

Expands accessibility for institutions utilizing GE HealthCare MRI systems Expands accessibility for institutions utilizing GE HealthCare MRI systems

FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems

GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.

GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strate.

GE HealthCare hosts 2024 Investor Day: focus on innovation to deliver precision care and drive growth

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed Journal of Clinical Anesthesia, highlighting performance of the wireless and wearable Portrait™ Mobile monitoring solution in the post-surgical ward environment. With published alarm rates from critical care and cardiac telemetry units that number in the hundreds per bed per day, healthcare systems may be concerned with.

Pilot Study Showcases the Value of Portrait Mobile Continuous Monitoring Solution to Encourage Clinical Intervention While Mitigating Alarm Fatigue

GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.

GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging

GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.

GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The FDA clearance of SIGNA MAGNUS underscores the advances made by GE HealthCare in neuroimaging. It features an innov.

GE HealthCare Receives FDA Clearance for Head-Only SIGNA MAGNUS 3.0T MRI System

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an initiative with AMN Healthcare aimed at helping address the critical shortage of radiologic technologists (rad tech) in the healthcare industry. This initiative helps healthcare providers meet their immediate staffing needs through AMN Healthcare's comprehensive workforce solutions and GE HealthCare's innovative technologies and training expertise. Several factors contributing to the current shortage of rad techs include.

GE HealthCare Announces Initiative to Help Address Radiologic Technologist Shortage

RadNet

Radnet Inc   (NASDAQ:RDNT) stock is soaring, last seen up 24% to trade at $89.11 at last glance, after the company reported better-than-expected earnings and revenue for the third quarter.

RadNet Stock Pops on Earnings, GE HealthCare Partnership

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced a strategic collaboration to further the innovation, commercialization, and adoption of AI in imaging. Together, the two companies aim to develop SmartTechnology™ solutions that harness the transformative power of AI to address key challenges across the imaging value chain, including helping i.

GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closin.

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Ae.

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required. The live webcast will be available at https://investor.gehealthcare.com/news-events/events.The press release, presentation, and w.

News for GE HealthCare Technologies Inc Stock (GEHC)